Quantitative Analysis of Cell-Free Epstein-Barr Virus DNA in Plasma of Patients with Nonnasopharyngeal Head and Neck Carcinomas

• Published in: Clinical cancer research 2004-03, Vol.10 (5), p.1726-1732
• Main Authors: Yu, Kwok Hung, Lo, Y M Dennis, Tse, Gary M, Chan, K C Allen, Chan, Amy B W, Chow, Katherine C K, Ma, Tony K F, Vlantis, Alexander C, Leung, Sing Fai, van Hasselt, C Andrew, Johnson, Philip J, Chan, Anthony T C
• Format: Article
• Language: English
• Subjects: Antineoplastic agents; Biological and medical sciences; Carcinoma, Squamous Cell - blood; Carcinoma, Squamous Cell - pathology; Carcinoma, Squamous Cell - virology; DNA, Viral - blood; DNA, Viral - genetics; DNA, Viral - isolation & purification; Gastritis - virology; Head and Neck Neoplasms - blood; Head and Neck Neoplasms - pathology; Head and Neck Neoplasms - virology; Herpesvirus 4, Human - genetics; Herpesvirus 4, Human - isolation & purification; Humans; Medical sciences; Neoplasm Staging; Pharmacology. Drug treatments; Polymerase Chain Reaction; Reference Values; Tumors
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-0991-3

Purpose: We investigated the detectability of EBV DNA in the plasma of patients with non-nasopharyngeal head and neck carcinomas (NNHNC). Previous studies have shown that EBV is present in the tumor tissue of some NNHNC. Experimental Design: We recruited 101 patients with NNHNC and 48 healthy controls. Blood samples were taken from controls and patients before treatment. Tumor tissue samples were tested for the presence of EBV in the first 69 patients by in situ hybridization for small EBV-encoded RNA (EBER). Plasma EBV DNA was measured by real-time quantitative PCR in patients and controls. Results: Squamous cell carcinoma (SCC) was the commonest histology (78 patients) followed by lymphoepithelial carcinoma (8 patients). EBER was detected in tumor cells in 7 of 69 patients tested. All of the EBER-positive tumors were lymphoepithelial carcinoma. Two controls (2 of 48; 4.2%) had detectable plasma EBV DNA. Plasma EBV DNA was detected in all of the patients with EBER-positive tumors, and in 23 of 94 (24.5%) patients with tumors of EBER-negative or unknown status. The proportion of plasma EBV DNA-positive cases in either group was significantly higher than that in the control group ( P < 0.0027). Plasma EBV DNA concentrations in patients with EBER-positive tumors (median, 3827 copies/ml) were significantly higher than those in the controls (median, 0 copy/ml; P = 0.0001). Of patients with SCC, 21 (26.9%) had detectable plasma EBV DNA (median concentration, 34 copies/ml). Plasma EBV DNA concentrations in the whole group of patients with SCC (median, 0 copy/ml; interquartile range, 0–4 copies/ml) were also significantly higher than those in the controls ( P = 0.001). Conclusions: Our data indicate that plasma EBV DNA reflects tumoral EBER status, and it may be of use as a tumor marker for EBER-positive NNHNC. The biological and clinical significance of low levels of circulating EBV DNA in the minority of patients with EBER-negative tumors remain to be elucidated.